Synjardy

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

empagliflozin i metformin

Available from:

Boehringer Ingelheim

ATC code:

A10BD20

INN (International Name):

empagliflozin, metformin

Therapeutic group:

Lijekovi koji se koriste u dijabetesu

Therapeutic area:

Dijabetes Mellitus, tip 2

Therapeutic indications:

Synjardy prikazan u odraslih osoba u dobi od 18 godina i stariji sa dijabetesom tipa 2 kao dodatak prehrani i fizičke vježbe za poboljšanje glikemijski kontrole kod pacijenata, neadekvatno kontroliranim o njihovo maksimalno переносимой dozi samo метформина;kod pacijenata, nedovoljno kontroliranim metforminom u kombinaciji s drugim сахароснижающих lijekova, uključujući inzulin;kod bolesnika koji su već liječeni kad kombinacije метформина i empagliflozin i kao pojedinačne tablete.

Product summary:

Revision: 26

Authorization status:

odobren

Authorization date:

2015-05-27

Patient Information leaflet

                                69
B. UPUTA O LIJEKU
70
UPUTA O LIJEKU: INFORMACIJE ZA BOLESNIKA
SYNJARDY 5 MG/850 MG FILMOM OBLOŽENE TABLETE
SYNJARDY 5 MG/1000 MG FILMOM OBLOŽENE TABLETE
SYNJARDY 12,5 MG/850 MG FILMOM OBLOŽENE TABLETE
SYNJARDY 12,5 MG/1000 MG FILMOM OBLOŽENE TABLETE
empagliflozin/metforminklorid
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili
medicinskoj sestri.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika, ljekarnika ili medicinsku
sestru. To uključuje i svaku moguću nuspojavu koja nije navedena u
ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je Synjardy i za što se koristi
2.
Što morate znati prije nego počnete uzimati Synjardy
3.
Kako uzimati Synjardy
4.
Moguće nuspojave
5.
Kako čuvati Synjardy
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE SYNJARDY I ZA ŠTO SE KORISTI
ŠTO JE SYNJARDY
Synjardy sadrži dvije djelatne tvari, empagliflozin i metformin. Obje
spadaju u skupinu lijekova koji
se nazivaju „oralni antidijabetici“. To su lijekovi koji se
uzimaju kroz usta radi liječenja šećerne
bolesti tipa 2.
ŠTO JE ŠEĆERNA BOLEST TIPA 2?
Šećerna bolest tipa 2 je bolest za koju su odgovorni i geni i način
života. Ako imate šećernu bolest
tipa 2, Vaša gušterača ne stvara dovoljno inzulina za kontrolu
razine glukoze u krvi, a Vaše tijelo ne
može učinkovito koristiti vlastiti inzulin. To rezultira visokim
razinama glukoze u krvi, što može
dovesti do medicinskih problema poput bolesti srca, bolesti bubrega,
sljepoće i slabe cirkulacije u
udovima.
KAKO SYNJARDY DJELUJE
Empagliflozin spada u skupinu lijekova koji se nazivaju inhibitori
suprijenosnika natrija i glukoze 2
(engl. _sodium-glucose co-transporter 2_, SGLT2)
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Synjardy 5 mg/850 mg filmom obložene tablete
Synjardy 5 mg/1000 mg filmom obložene tablete
Synjardy 12,5 mg/850 mg filmom obložene tablete
Synjardy 12,5 mg/1000 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Synjardy 5 mg/850 mg filmom obložene tablete
Jedna tableta sadrži 5 mg empagliflozina i 850 mg metforminklorida.
Synjardy 5 mg/1000 mg filmom obložene tablete
Jedna tableta sadrži 5 mg empagliflozina i 1000 mg metforminklorida.
Synjardy 12,5 mg/850 mg filmom obložene tablete
Jedna tableta sadrži 12,5 mg empagliflozina i 850 mg
metforminklorida.
Synjardy 12,5 mg/1000 mg filmom obložene tablete
Jedna tableta sadrži 12,5 mg empagliflozina i 1000 mg
metforminklorida.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta (tableta).
Synjardy 5 mg/850 mg filmom obložene tablete
Žućkasto bijele, ovalne, bikonveksne filmom obložene tablete s
oznakom „S5“ i logom Boehringer
Ingelheim utisnutima na jednoj te oznakom „850“ na drugoj strani
(duljina tablete: 19,2 mm, širina
tablete: 9,4 mm).
Synjardy 5 mg/1000 mg filmom obložene tablete
Smećkasto žute, ovalne, bikonveksne filmom obložene tablete s
oznakom „S5“ i logom Boehringer
Ingelheim utisnutima na jednoj te oznakom „1000“ na drugoj strani
(duljina tablete: 21,1 mm, širina
tablete: 9,7 mm).
Synjardy 12,5 mg/850 mg filmom obložene tablete
Roskasto bijele, ovalne, bikonveksne filmom obložene tablete s
oznakom „S12“ i logom Boehringer
Ingelheim utisnutima na jednoj te oznakom „850“ na drugoj strani
(duljina tablete: 19,2 mm, širina
tablete: 9,4 mm).
Synjardy 12,5 mg/1000 mg filmom obložene tablete
Tamnosmećkasto ljubičaste, ovalne, bikonveksne filmom obložene
tablete s oznakom „S12“ i logom
Boehringer Ingelheim utisnutima na jednoj te oznakom „1000“ na
drugoj strani (duljina tablete:
21,1 mm, širina tablete: 9,7 mm).
3
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Synjardy je indiciran 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-09-2023
Public Assessment Report Public Assessment Report Bulgarian 05-07-2017
Patient Information leaflet Patient Information leaflet Spanish 27-09-2023
Public Assessment Report Public Assessment Report Spanish 05-07-2017
Patient Information leaflet Patient Information leaflet Czech 27-09-2023
Public Assessment Report Public Assessment Report Czech 05-07-2017
Patient Information leaflet Patient Information leaflet Danish 27-09-2023
Public Assessment Report Public Assessment Report Danish 05-07-2017
Patient Information leaflet Patient Information leaflet German 27-09-2023
Public Assessment Report Public Assessment Report German 05-07-2017
Patient Information leaflet Patient Information leaflet Estonian 27-09-2023
Public Assessment Report Public Assessment Report Estonian 05-07-2017
Patient Information leaflet Patient Information leaflet Greek 27-09-2023
Public Assessment Report Public Assessment Report Greek 05-07-2017
Patient Information leaflet Patient Information leaflet English 27-09-2023
Public Assessment Report Public Assessment Report English 05-07-2017
Patient Information leaflet Patient Information leaflet French 27-09-2023
Public Assessment Report Public Assessment Report French 05-07-2017
Patient Information leaflet Patient Information leaflet Italian 27-09-2023
Public Assessment Report Public Assessment Report Italian 05-07-2017
Patient Information leaflet Patient Information leaflet Latvian 27-09-2023
Public Assessment Report Public Assessment Report Latvian 05-07-2017
Patient Information leaflet Patient Information leaflet Lithuanian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-09-2023
Public Assessment Report Public Assessment Report Lithuanian 05-07-2017
Patient Information leaflet Patient Information leaflet Hungarian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 27-09-2023
Public Assessment Report Public Assessment Report Hungarian 05-07-2017
Patient Information leaflet Patient Information leaflet Maltese 27-09-2023
Public Assessment Report Public Assessment Report Maltese 05-07-2017
Patient Information leaflet Patient Information leaflet Dutch 27-09-2023
Public Assessment Report Public Assessment Report Dutch 05-07-2017
Patient Information leaflet Patient Information leaflet Polish 27-09-2023
Public Assessment Report Public Assessment Report Polish 05-07-2017
Patient Information leaflet Patient Information leaflet Portuguese 27-09-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 27-09-2023
Public Assessment Report Public Assessment Report Portuguese 05-07-2017
Patient Information leaflet Patient Information leaflet Romanian 27-09-2023
Public Assessment Report Public Assessment Report Romanian 05-07-2017
Patient Information leaflet Patient Information leaflet Slovak 27-09-2023
Public Assessment Report Public Assessment Report Slovak 05-07-2017
Patient Information leaflet Patient Information leaflet Slovenian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 27-09-2023
Public Assessment Report Public Assessment Report Slovenian 05-07-2017
Patient Information leaflet Patient Information leaflet Finnish 27-09-2023
Public Assessment Report Public Assessment Report Finnish 05-07-2017
Patient Information leaflet Patient Information leaflet Swedish 27-09-2023
Public Assessment Report Public Assessment Report Swedish 05-07-2017
Patient Information leaflet Patient Information leaflet Norwegian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 27-09-2023
Patient Information leaflet Patient Information leaflet Icelandic 27-09-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 27-09-2023

Search alerts related to this product

View documents history